KBC Group NV Purchases 559 Shares of Inari Medical, Inc. (NASDAQ:NARI)

KBC Group NV increased its position in Inari Medical, Inc. (NASDAQ:NARI) by 31.5% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 2,333 shares of the company’s stock after buying an additional 559 shares during the quarter. KBC Group NV’s holdings in Inari Medical were worth $119,000 at the end of the most recent reporting period.

A number of other institutional investors have also bought and sold shares of the business. GAMMA Investing LLC lifted its position in shares of Inari Medical by 67.2% in the third quarter. GAMMA Investing LLC now owns 1,177 shares of the company’s stock valued at $49,000 after acquiring an additional 473 shares in the last quarter. Cerity Partners LLC raised its stake in Inari Medical by 2.8% during the 3rd quarter. Cerity Partners LLC now owns 24,056 shares of the company’s stock valued at $992,000 after purchasing an additional 652 shares during the period. Covestor Ltd lifted its holdings in Inari Medical by 63.5% in the 3rd quarter. Covestor Ltd now owns 2,384 shares of the company’s stock worth $99,000 after purchasing an additional 926 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. boosted its stake in Inari Medical by 44.2% in the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,113 shares of the company’s stock worth $128,000 after purchasing an additional 954 shares during the period. Finally, Asset Management One Co. Ltd. grew its holdings in Inari Medical by 1.6% during the 3rd quarter. Asset Management One Co. Ltd. now owns 61,354 shares of the company’s stock valued at $2,530,000 after buying an additional 962 shares in the last quarter. Hedge funds and other institutional investors own 90.98% of the company’s stock.

Inari Medical Price Performance

Shares of NARI stock opened at $79.76 on Friday. The company has a market cap of $4.67 billion, a PE ratio of -59.08 and a beta of 1.02. Inari Medical, Inc. has a 1 year low of $36.73 and a 1 year high of $79.93. The stock’s 50 day simple moving average is $65.69 and its two-hundred day simple moving average is $53.26.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on NARI shares. Canaccord Genuity Group restated a “hold” rating and set a $80.00 target price (up previously from $74.00) on shares of Inari Medical in a research report on Tuesday, January 7th. Truist Financial increased their price objective on shares of Inari Medical from $50.00 to $63.00 and gave the company a “hold” rating in a report on Wednesday, December 18th. Piper Sandler raised their price objective on Inari Medical from $52.00 to $80.00 and gave the company a “neutral” rating in a research report on Tuesday, January 7th. Oppenheimer began coverage on Inari Medical in a research report on Tuesday, December 17th. They issued an “outperform” rating and a $75.00 target price on the stock. Finally, Needham & Company LLC restated a “hold” rating on shares of Inari Medical in a report on Tuesday, October 29th. Twelve analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $68.00.

Insider Activity

In other Inari Medical news, Director William Hoffman sold 200,000 shares of Inari Medical stock in a transaction on Monday, January 6th. The shares were sold at an average price of $60.47, for a total transaction of $12,094,000.00. Following the completion of the transaction, the director now directly owns 238,987 shares of the company’s stock, valued at $14,451,543.89. The trade was a 45.56 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Andrew Hykes sold 3,000 shares of the stock in a transaction on Friday, December 20th. The shares were sold at an average price of $55.29, for a total transaction of $165,870.00. Following the completion of the sale, the chief executive officer now directly owns 439,310 shares in the company, valued at approximately $24,289,449.90. This represents a 0.68 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 323,000 shares of company stock valued at $18,669,070. 10.60% of the stock is currently owned by insiders.

Inari Medical Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.